Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbot Medical ( (MBOT) ) has provided an announcement.
On April 13, 2026, Microbot Medical announced it had successfully completed the limited market release of its LIBERTY Endovascular Robotic System and would launch a full market release in the U.S. at the Society of Interventional Radiology Annual Scientific Meeting in Toronto, held April 11–15, 2026. During the limited rollout, LIBERTY was adopted by multiple healthcare systems with dozens of hospitals, including Emory Healthcare and Tampa General Hospital, and was used commercially across procedures such as PAE, UFE, GAE, Y90 work and peripheral arterial interventions.
LIBERTY, described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, has been praised by physicians for its precision, ease of use, and potential to shorten procedure times and reduce instrument use. To support the nationwide rollout, Microbot has doubled its U.S. sales footprint from four to eight territories and plans to expand to 12 by the end of 2026, underscoring a strategic push to capitalize on growing demand for radiation- and ergonomics-focused solutions in interventional radiology.
The full market launch at SIR coincides with newly adopted radiation safety and musculoskeletal risk guidelines from SIR, CIRSE and other medical societies, as well as recent AMA policy to bolster protections from ionizing radiation. Microbot aims to leverage this regulatory and professional focus on clinician safety by showcasing LIBERTY to its primary target users at the conference, seeking to accelerate adoption and deepen penetration in existing and new hospital networks across the U.S.
The most recent analyst rating on (MBOT) stock is a Buy with a $5.50 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution designed to improve precision, efficiency and safety in peripheral endovascular care.
Backed by a sizable intellectual property portfolio, Microbot targets interventional radiology and related specialties as its primary U.S. market. The company positions LIBERTY as a new category of endovascular robotics aimed at reducing radiation exposure and physical strain for clinicians while addressing key clinical and operational challenges in hospitals and large healthcare systems.
Average Trading Volume: 2,047,059
Technical Sentiment Signal: Buy
Current Market Cap: $173.9M
Learn more about MBOT stock on TipRanks’ Stock Analysis page.